Oncology

Vitamin A combined with Gemzar found to reduce proliferation of cancer cells.

Researchers still urge physicians to use caution utilizing light phototherapy for jaundice infants.

Xilonix is the first monoclonal antibody immunotherapy that targets and neutralizes interleukin-1 alpha.

Malignant brain tumor cells found to rely on fats for energy and growth.

Radiation therapy with checkpoint inhibitors offers promise for skin cancer therapy.

Top news of the day from across the health care landscape.

Researchers were able to better predict the risk of developing breast cancer.

System provides images deep within tumor tissue.

On February 17, 2017, a pharmacist will be climbing Mount Kilimanjaro to support the Multiple Myeloma Research Foundation.

Mice without the LRH-1 protein develop less liver cancers than mice who had the protein.

Olive oil-based emulsion may help boost efficacy of bladder cancer therapy.

Approximately 58% of patients with nonalcoholic steatohepatitis treated with pioglitazone showed reduced disease activity.

Photodynamic therapy for skin cancer can cause immense burning pain to patients.

The protein GlyRS helps modify proteins that cause cancer growth.

Research may lead to new treatments for ovarian cancer.

Doxorubicin, all-trans retinoic acid, and entinostat significantly reduced triple-negative breast cancer tumors in mice.

Driver mutations in lung adenocarcinoma and lung squamous cell carcinoma differ from one another, contradictory to previous theories.

Findings improve the ability of providers to monitor the development of melanoma.

Anthrax toxin proteins are able to control tumor growth.

If cancerous tumors have an addiction to a gene, an inhibitor can be administered that can stop cell growth.

Postmenopausal patients with invasive ductal carcinomas had high levels of saturated fats.

Researchers find indicators of poor chemotherapy response.

Women older than age 65 face higher risk for several comorbidities from breast cancer treatment.

Recent advances and updates in oncology and cancer drug development.

Uncialamycin may effectively treat various cancer types, including gastric, lung, and ovarian cancers.

Blocking the chemokine CXCL1 resulted in slowed growth of obesity-related prostate cancer in mice models.

Individuals with primary immunodeficiency carry increased risk of developing a variety of cancers.

The drug eCF506 can selectively block the Src tyrosine kinase and stop the growth of breast cancer cells.